News | March 31, 2026
Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The presentations underscore the company’s deep expertise in dermatology and immunology
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Subscribe To Our Newsletter & Stay Updated
